Australia, Feb. 27 -- Tangram Therapeutics PLC, owns the trademark (2593179) for 'TANGRAM' till Aug. 21, 2035.

Status: protected: Registered/protected

Classes: 5 [Pharmaceutical and medical preparations; pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals; short interfering RNA (siRNA) medicines and pharmaceuticals; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation.], 9 [Computer software for use in the field of pharmaceuticals, medicines and drug discovery; artificial intelligence and machine learning software; artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery; databases; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery; computer platform software platforms for use in the field of pharmaceuticals, medicines and drug discovery; computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery.], 40 [Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid.] and 42 [Scientific research and development; pharmaceutical research and development services; scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; genetic research; scientific and technical data analysis; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services for use in the fields of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in relation to RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models; design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services for use in the fields of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning in relation to RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation]

Type of Mark: Word

Date of Acceptance: Dec. 19, 2025

Registration Advertised: Feb. 26

For further details contact Banki Haddock Fiora and CMS Cameron McKenna Nabarro Olswang LLP .

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2593179.

Disclaimer: Curated by HT Syndication.